SCHEMBL62329

SCHEMBL62329

O=C(NCc1ccc(F)cc1)c1nc2n(c(=O)c1O)CC1CNCC2C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.51
CYP2C9 P11712 1/20 0.51
ERCC1 P07992 1/20 0.42
FEN1 P39748 1/20 0.42
ERCC4 Q92889 1/20 0.42
CHRNB2 P17787 2/20 0.41
CHRNB4 P30926 2/20 0.41
CHRNA3 P32297 2/20 0.41
CHRNA4 P43681 2/20 0.41
CHRNA7 P36544 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KCNE1 P15382 1/20 0.41
CCR1 P32246 1/20 0.41
KCNQ1 P51787 1/20 0.41
CALCA P06881 1/20 0.39
GAA P10253 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
LIPG Q9Y5X9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13691554 0.89 KCNH2 (0.55) KCNH2CYP2C9ERCC1FEN1ERCC4
SCHEMBL61799 0.87 KCNH2 (0.56) KCNH2CYP2C9ERCC1FEN1ERCC4
SCHEMBL52622 0.80 KCNH2 (0.52) KCNH2CYP2C9ERCC1FEN1ERCC4
SCHEMBL63435 0.79 KCNH2 (0.46) KCNH2CYP2C9ERCC1FEN1ERCC4
SCHEMBL63257 0.78 KCNH2 (0.53) KCNH2CYP2C9ERCC1FEN1ERCC4
SCHEMBL51960 0.78 KCNH2 (0.54) KCNH2CYP2C9ERCC1FEN1ERCC4
SCHEMBL63436 0.78 KCNH2 (0.56) KCNH2CYP2C9ERCC1FEN1ERCC4
SCHEMBL13691593 0.76 KCNH2 (0.52) KCNH2CYP2C9ERCC1FEN1ERCC4
SCHEMBL51888 0.76 KCNH2 (0.51) KCNH2CYP2C9ERCC1FEN1ERCC4
SCHEMBL2208851 0.76 KCNH2 (0.54) KCNH2CYP2C9ERCC1FEN1ERCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885ERCC1 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.